Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture and fill-finish for preclinical and clinical programs for therapeutics that do not have effective manufacturing protocols.
The therapeutics include vaccines, autologous therapeutics, new gene therapeutic platforms and stem cell technologies.
Omnia Biologics CEO Dale VanderPutten said they have offered liquid formulated and lyophilized process development, cGMP manufacture, formulation and stability services.
"we have seen the process and stabilization advantages of spray drying especially as it relates to improved ambient stability for vaccines important in developing economies," VanderPutten said.